Abstract
There are different arrangements by which a radiopharmaceutical can be studied in humans. The metabolim and pharmacology of derivatives of approved drugs can be studied under the mechanism of the Research Drug Research Committee (RDRC). The procedures, safeguards and safety issues are reviewed and approved by an institutional committee, which in turn is answerable to regulatory agencies. For studies involving efficacy for either diagnostic or therapeutic clinical application, an Investigational New Drug exemption must be requested. Details of manufacture, testing, and safety must be submitted to US FDA in a formal application. Such an IND study may be sponsored by a company intending to commercialize a product or by physicians studying a disease state. Before the product may be sold or distributed, a New Drug Application (NDA) must be filed and approved by the FDA. Once approved, the radiopharmaceutical can be routinely prescribed in clinical practice.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baldwin, R. M., Lin, T. H., and Wu, J-L., 1982, Synthesis and brain uptake of isomeric 123I-iodoamphetamine derivatives, J. Lab. Compd. Radiopharm. 19: 1305.
Baldwin, R. M., Wu, J-L., Lin, T. H., Salazar, N. E., Ma, J. M., Look, S., Vu, C. D., Borenstein, J., Reele, S., Hain, D., and Felix, M. J., 1986, Pharmacokinetics of I-123 Nisopropyl-p-iodoamphetamine (IMP) in humans, in “Current Applications in Radiopharmacology,” M. V. Billinghurst, ed., Pergamon Press, Toronto.
Blaschke, G. and Donow, F., 1975, Polymere 1-PhenyläthylaminDerivate als optisch aktive Adsorbentien, Chem. Ber. 108: 2792.
Borch, R. F., Bernstein, M. D., and Durst, H. D., 1971, The cyanohydridoborate anion as a selective reducing agent, J. Am. Chem. Soc., 93: 2897.
van Wyck, A. J., Fourie, P. J., van Zyl, W. H., Lötter M. G., and Minnaar, P. C., 1979, Synthesis of five new 99mTc HIDA isomers and comparison with 99mTc HIDA, Eur. J. Nucl. Med., 4: 445.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Baldwin, R.M. (1991). Identity, Strength, Purity, Quality, and Safety: Common Goals for New Drugs. In: Emran, A.M. (eds) New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0626-7_36
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0626-7_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0628-1
Online ISBN: 978-1-4899-0626-7
eBook Packages: Springer Book Archive